Exploring Pembrolizumab‐Induced IM3OS in a Patient With Bladder Cancer
ABSTRACT Pembrolizumab, an immune checkpoint inhibitor (ICI), has transformed cancer treatment across various malignancies, including metastatic urothelial cancer. As the use of pembrolizumab becomes increasingly widespread, understanding its potential adverse effects is essential. Here, we present...
Gardado en:
| Principais autores: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Wiley
2026-02-01
|
| Series: | Pharmacology Research & Perspectives |
| Acceso en liña: | https://doi.org/10.1002/prp2.70212 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|